Drug intelligence / Profile preview

SRI-9439

Development stage: Preclinical
Lead developer: Southern Research
Modality: Small Molecules

Overview

SRI-9439 is a potent lipophilic antifolate inhibitor developed by Southern Research Institute. It targets and inhibits human dihydrofolate reductase (hDHFR), forming a ternary complex with NADPH. The drug was initially developed against *Toxoplasma gondii* DHFR-thymidylate synthase, indicating its potential as an anti-infective agent. Its crystal structure in complex with hDHFR and NADPH has been determined at atomic resolution, providing insights into its binding characteristics and inhibitory activity.

Other names: 6-([5-quinolylamino]methyl)-2,4-diamino-5-methylpyrido[2,3-d]pyrimidine

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on SRI-9439.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRI-9439.